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ABSTRACT
Current treatment of cutaneous leishmaniasis (CL) relies mainly on pentavalent antimonials salts and second-line drugs 
include pentamidine and amphotericin B, but these therapies have side effects and require parenteral administration. The 
aim of this work was to evaluate the topical formulations containing pentamidine isethionate (PI) in the experimental 
treatment of cutaneous leishmaniasis (CL). Golden hamsters (Mesocricetus auratus) were infected in the nose with Leishmania 
(Leishmania) amazonensis. Six treatment groups received different topical treatments of anhydrous or hydrating emulsions, 
for a maximum of 10 days, with an application of 50 mg day-1. After treatment tissue samples of lesions were evaluated by 
histology, transmission electron microscopy and biopsy cultivation. Compared with untreated group, topical treatment with 
hydrating emulsion with 10% PI and usnic acid (ACE5AU) showed significantly decrease in volume lesion (P= 0.028) on 20th 
day after the end of the treatment with reduction of 27.37%. Topical treatment with anhydrous emulsion with 10% PI and 
usnic acid (ACPU) reduces parasite burden in Golden hamsters. This study demonstrated the potential of topical treatment 
to reduce the number of parasites that could be combined with others drugs and to have a faster and more effective treatment 
of cutaneous leishmaniasis.
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Tratamento tópico da leishmaniose cutânea experimental em golden  
hamsters (Mesocricetus auratus) com fórmulas contendo pentamidina
RESUMO
O tratamento atual para Leishmaniose Tegumentar Americana é realizado com antimoniais pentavalentes como tratamento 
padrão, e as drogas de segunda escolha incluem pentamidina e anfotericina B, mas essas terapias apresentam efeitos colaterais 
e requerem administração parenteral. O objetivo deste trabalho foi avaliar formulações tópicas contendo isetionato de 
pentamidina comercial (IP) no tratamento da leishmaniose cutânea experimental (LC). Hamsters dourados foram infectados 
no focinho com Leishmania (Leishmania) amazonensis. Grupos de seis animais receberam tratamento tópico com cremes 
anidro ou emulsões hidratantes, num máximo de 10 dias, com aplicação de 50 mg dia-1. Amostras de tecido de lesões tratadas 
foram avaliadas por histologia, microscopia eletrônica de transmissão (MET) e cultivo de biópsia. Comparado ao grupo sem 
tratamento, o tratamento tópico com emulsão hidratante com 10% de IP e ácido úsnico (ACE5AU) mostrou diminuição 
significativa (P=0,028) nas medidas de lesões, 20 dias após o final do tratamento e 27,37% de redução. O tratamento tópico 
com emulsão anidra com 10% de IP e ácido úsnico (ACPU) mostrou redução da carga parasitária em Golden hamsters. Este 
estudo demonstrou a possibilidade de utilizar o tratamento tópico para reduzir o número de parasitas e que este poderia ser 
associado a outras drogas para tratamento mais rápido e eficaz da leishmaniose cutânea.
PALAVRAS-CHAVE: formulações tópicas, isetionato de pentamidina, tratamento experimental, modelo animal, Leishmania
 40 VOL. 47(1) 2017: 39 - 46    COMANDOLLI-WYREPKOWSKI et al.
Topical treatment of experimental cutaneous leishmaniasis in golden hamster 




Leishmaniasis is a chronic inflammatory infectious and 
parasitic disease caused by obligatory intracellular parasites of 
the genus Leishmania (Murray et al. 2005) that affect different 
types of tissue depending on the species involved (Guizani et al. 
2011). Leishmaniasis is a public health issue in 98 countries, 
and there is an annual occurrence of two million new cases 
reported each year. In addition, more than 15 million people 
are infected Worldwide in a risk area that encompasses more 
than 350 million people (Alvar et al. 2012). Reports of 
epidemics have occurred in the Northeast of Brazil and Amazon 
region related to predatory colonization processes (Pinheiro 
et al. 2008). Leishmania is transmitted by insect vector, 
Phlebotomus species in the Old World and Lutzomyia species 
in the New World (Bates 2007). Treatment of leishmaniasis is 
still very limited and depends on the clinical way the disease 
manifests (cutaneous or visceral). The pentavalent antimonial 
salt such as N-methylglucamine antimonate (Glucantime®) 
and sodium stibogluconate (Pentostam®) remain the first-line 
drugs for the treatment of leishmaniasis for over 50 years 
(Almeida and Santos 2011), but they are strongly associated 
with numerous side effects. In addition to antimony, other 
drugs have been used in the treatment of various forms of 
leishmaniasis, among which we highlight: Pentamidine, 
Amphotericin B, miltefosine and paromomycin (Rath et al. 
2003). However, each of these therapies has serious limitations, 
including long-term parenteral administration, toxic side 
effects, high cost in endemic countries, and a large number of 
cases of resistance, predominantly associated with co-infection 
with the human immunodeficiency virus (HIV) [Croft et al. 
2006]. Pentamidines are aromatic diamidines that have been 
used as second-line drugs in the treatment of Leishmaniasis 
in endemic areas (Singh et al. 2012) and commercialized for 
use in humans in the following formulations: isethionate 
(Di-hydroxyethane-sulfonate B) and mesylate (B-Di-
Hydroxymethyl-sulfonate) [Alvar et al. 2006]. The discovery of 
the antiprotozoal activity of diamidines has led to the demand 
for hypoglycemic compounds that could compromise energy 
metabolism of parasites (Croft et al. 2006).  Pioneering studies 
with topical formulations [Topical treatment (TT)] to the 
treatment of leishmaniasis were performed by El-On et al. 
(1986), using preparations of antibiotics of the aminoglycoside 
class, paromomycin, using 15% paromomycin sulphate 
and 12% methyl benzethonium chloride in a hydrophobic 
base treatment of cutaneous leishmaniasis (CL) caused by 
Leishmania (Leishmania) major. The development of topical 
formulations could be an alternative method for the treatment 
of CL. Although the transdermal transport of drugs has many 
advantages over other routes of administration, there are still 
problems that need to be investigated, such as low penetration 
of most compounds through the human skin (Rossi-Bergmann 
et al. 2011). The aim of this study was to investigate the effects 
of topical treatment with formulations containing pentamidine 
isethionate/PI (Pentacarinat®/Sanofi) in experimentally 
induced leishmanasis in Golden hamsters (Mesocricetus auratus) 
infected with Leishmania (Leishmania) amazonensis. 
MATERIALS AND METHODS
Origin and maintenance of parasites: The strain 
MHO/BR/2006/IM5584 of L. (L.) amazonensis, was 
characterized, cryopreserved and kept in the Laboratory of 
Leishmaniasis and Chagas´s Disease, Research Coordination 
of Environment, Society and Health, National Institute 
of Amazonian Research – INPA, Amazonas, Brazil. The 
parasites were grown in a biphasic medium NNN, and the 
culture was expanded in complete RPMI medium 1640 
(Himedia), supplemented with 10% inactivated fetal calf 
serum (iFCS), gentamycin (40 µg mL-1) and cryopreserved 
in liquid nitrogen. 
Production of the formulations: Six different topical 
formulations were prepared using Polawax® as emulgent and 
30% of commercial vegetable oils Andiroba (A) and Copaiba 
(C) for hydrating creams and 50% of oils for anhydrous 
creams. Methylparaben and propylparaben were both used 
as preservatives. All formulations are non-ionic emulsion 
creams produced by the phase inversion method. Hydrating 
creams were: ACE0B (containing only oils, emulgent and 
preservatives) ACE5A (10% PI [pentamidine isethionate 
(Pentacarinat®/Sanofi]) and ACE5AU (10% PI and 10% of 
usnic acid), and the anhydrous emulsions were: ACP (10% 
of PI), ACPU (10% of PI and 10% of usnic acid) and ACU 
(10% of usnic acid).  
Origin and infection of animals: Experimental animals 
used were 60 golden hamsters, all adult males from the 
Central Animal Laboratory of INPA, kept in cages in rooms 
conditioned with photoperiod, temperature constant, 
feeding conditions ad libitum and pathogens free (Project 
approved by Ethic Committee in Animal Research of the 
National Institute for Amazonian Research / INPA-CEUA, 
registration/approval number 009/2012).  
Experimental design: The animals were separated into 
experimental groups, in nose of each one was inoculated 
with 0.01 mL of L. (L.) amazonensis promastigotes (106 cells.
mL-1). The animals remained under supervision for 21 days 
until the appearance of lesions. After the lesions established, 
they were measured to ensure homoscedasticity of treatment 
groups for the total volume of the lesion. The animals were 
used in two separate experiments: I – a total of 36 hamsters 
were infected and separated into three separate groups for 
topical treatments with hydrating creams ACE5A, ACE5AU, 
ACE0B and a control group without treatment (negative 
control/NC). The treatment groups received an emulsion 
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applied to the lesion, 50 mg day-1, for eight consecutive days. 
The animals remained under observation with data collection 
for over 32 days without treatment. The test subjects for this 
experiment were euthanized 40 days after the trial; II - 24 
hamsters infected, separated in groups for topical treatments 
with anhydrous creams ACP, ACPU, ACU, and a control 
group that did not receive a treatment (NC). The treatment 
groups received an emulsion at the lesion site with 50 mg 
day-1, for 10 consecutive days and the animals were kept under 
observation for 20 days. The test subjects for this experiment 
were euthanized 30 days after the trial.  
Evaluation of treatment effects: Clinical evaluation: 
Each animal was subjected to daily evaluation to determine 
the amounts of the total lesion volume (length, width and 
height) using pachymeter (Zaas Precision®) to analyze the 
progression of the lesion. The numerical data were then 
recorded, tabulated and analyzed statistically. Lesions were 
also photo documented for the analysis of morphological 
evolution. Euthanasia: The animals were euthanized with 
Euthanyle® (sodium pentobarbital - phenytoin sodium) 
in accordance with the INPA´s commission on the ethical 
treatment of animals. Parasitological studies: A tissue sample 
sectioned from the lesion area of each animal was used for 
an imprint on glass slides. The slides were stained with 
Giemsa (Sigma), and the infectivity index was determined 
by multiplying the percentage of macrophages that had at 
least one intracellular parasite by the average number of 
intracellular parasites per infected macrophage (at least 200 
cells were examined/animal). Viability of parasites in culture 
medium: Tissue fragments of lesions were cultivated in 
NNN medium for eight days at 25 oC to observe the parasite 
viability. Tissue samples were sectioned from each area of the 
animal lesion. The dimensions of 1.0 x 1.0 x 1.0 mm were 
fixed in glutaraldehyde in 0.1 M of cacodylate buffer (2.5% 
v/v) and underwent analysis by Transmission Electronic 
Microscoscopy (TEM). Blocks were prepared with an Epoxy 
– Embedding Kit (Sigma-aldrich®), and the experiments 
were performed on a FEI TECNAI G12 Spirit-Twin (120 
kV, LaB6) microscope equipped with a FEI Eagle 4k CCD 
camera (Eindhoven, The Netherlands). Prior to observations, 
thin sections of the samples (nominal thickness 100 nm) were 
obtained by a Leica UC7 ultramicrotome (Wien, Austria) 
and placed on 400 mesh copper grids. Statistical analysis: It 
was performed using the GraphPad Prism software (version 
6.0 for Windows). A one-way ANOVA statistical test was 
used to assess the significance of the differences between 
the various groups followed by Tukey’s test to compare the 
means of different treatment groups, with 95% confidence 
to be considered significant. 
RESULTS
Evaluation of lesion size is an important parameter, mainly 
in the species that we can observe with nodular lesions with 
the presence of histiocytomas. Nodular lesions caused by 
L. (L.) amazonensis developed 21 days after inoculation, 
followed by ulceration in 63 days post infection. 
The topical treatment (TT) was initiated 21 days post 
infection. Figure 1 shows the results of the evolution of 
the lesion volume in relation to the days of application and 
observation after the end of the treatment with hydrating 
creams and anhydrous creams.  The average size of the lesions 
remained under steady growth in 30 to 40 days after initiation 
of treatment and progression to ulcerated lesions may be 
observed in certain animals.  
Among the hydrating creams, ACE5AU formulation 
demonstrated effectiveness in the clinical aspect and efficiency 
by reducing the total volume of lesions, compared with the 
average of the control group (Figure 1-A). The ACE0B cream 
Figure 1. Effect of topical treatment on lesion growth using different 
formulas. Golden Hamsters (Mesocricetus auratus) infected with Leishmania 
(Leishmania) amazonensis, during and after topical treatment with 50 mg 
day-1of  A – hydrating creams; B – anhydrous creams.  Control: animals 
inoculated but without topical treatment. The data represent the mean ± SD 
from 6 hamster/group. *p<0.05 when compared with all groups.
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caused a swelling and redness of the injury. The statistical test 
shows a significant difference between the ACE5AU group 
and the control group after 20 days at the end of the topical 
treatment (P = 0.0282), and this was the difference in increase 
after 30 days (P < 0.0001). Animals treated with formulation 
ACE5A showed a difference in lesion size when compared 
with the control group on the 40th day (P =0.0164).  Thus, 
the ACE5AU group showed a difference compared with the 
ACE5A group on the 40th day of trial (P = 0.0158). Lesions 
of the hamsters snout that received a treatment of ACE0B 
(no pentamidine, only constituents of cream) showed no 
significant differences between the control group (P > 0.05). 
The average size of the lesions remained stable in the ACE5AU 
group during treatment, with a small increase in size after 
treatment, unlike the other groups that showed an increase 
in the lesion area. The average size of lesions in the ACE5AU 
group showed a reduction of 27.37% when compared with 
the control group on 40th day of trial. 
 Development of the lesions in the groups that received 
treatment with anhydrous creams (Figure 1-B) showed no 
statistically significant difference in the average volume of lesions 
during 10 days of topical treatment. However, the follow-up of 
the infection after treatment which was observed on the 20th 
day of the trial revealed that the control group had a significant 
increase in lesions, while the other groups that received a topical 
treatment had a constant amount of lesions. Statistical analysis 
showed that the three treatment groups, ACP, ACPU and 
ACU differed significantly from the control group (P<0.05) 
from the 20th day until the end of the observation. The ACP 
group appeared to have a smaller average size of lesions with 
the anhydrous treatments, which had a statistically significant 
difference of NC (P = 0.0056) on 30th day of trial. However, 
no statistical difference appeared between groups treated with 
anhydrous formulations. The average size of lesions for the ACP 
treatment group demonstrated a reduction of 26.63% when 
compared with control group on the 30th day of trial.
Histological analyses of the imprints undergoing treatment 
with hydrating creams also showed the presence of amastigotes, 
a form of  L. amazonensis, in all treated animals (Figure 2A, B). 
Parasite burden in lesions of treatments ACE5A and ACE5AU 
demonstrated a significant decrease. Statistical differences 
were observed between the ACE5A and ACE5AU treatments 
when comparing the percentages of amastigotes to the control 
groups (P<0.001) Thus, quantity of amastigotes in the ACE0B 
group and control groups, showed no statistical difference (P = 
0.3915). The average percentage of infected macrophages did 
not show a statistical difference in any treatment group. Analysis 
of the mean values  of the parasite burden present in the samples 
of the anhydrous groups showed a statistical difference with the 
control group when the quantity of parasites in ACP TT (P = 
0.0327) and ACPU TT (P = 0.002) were compared. However, 
the percentages of infected macrophages present in imprints 
showed a significant difference only between the ACPU group 
and the control group (P = 0.0309).  
A difference in clinical morphology of nose was observed 
for the treatment with ACE0B which induced a lesion area of 
swelling.  The swelling in the nose of the treated hamsters had 
a glossy appearance, which only occurred after applying the 
formulation. This fact was also observed in ACE5A group (Figure 
3D), but to a lesser extent. The group treated with ACE5AU also 
showed less swelling, and some of the animals started the process 
of scar and ulceration in the lesion area. In the control groups, 
the lesions remained without an increase in scabbing or scarring 
or sleek appearance of edema. The clinical appearance of lesions 
of the anhydrous treated groups showed no specific property to 
some group having the animals cells showing injury to production 
in virtually all groups. 
Viability of the parasite in NNN after culturing fragments 
of lesions showed the presence of active parasites in all samples 
obtained from animals treated, with anhydrous and hydrating 
formulations, after eight days of incubation. This data was only 
Figure 2. Inhibition of parasite growth by the topical treatment with formulas. 
The data represent the mean values of the infection index counted by imprinting 
lesions fragments stained with Giemsa and counted in 1000 X. A - hydrating 
creams; B – anhydrous creams. Control: animals inoculated but without topical 
treatment. The data represent the mean ± SD from 6 hamster/group. *p < 
0.05 when compared with all groups.
 43 VOL. 47(1) 2017: 39 - 46    COMANDOLLI-WYREPKOWSKI et al.
ACTA
AMAZONICA Topical treatment of experimental cutaneous leishmaniasis in golden hamster (Mesocricetus auratus) with formulations containing pentamidine
such as cytoplasmic vacuoles and vesicles in groups treated with 
cream containing pentamidine, as in the ACP group. 
DISCUSSION
Although the parenteral treatment with PI is reported as 
the second choice for the treatment of leishmaniasis (Berman 
2005; Minodier and Parola 2007; Mitropoulos et al. 2010), 
the PI has the advantage of a short time span and may be used 
in individuals intolerant to antimonial treatment (Mitropoulos 
et al 2010). No data for topical treatment applications has been 
reported to date with topical formulations containing PI.  
A study in Colombia showed a 96% cure of CL in 51 
patients who received a total of 4 PI injections of 3 mg kg-1day-1 
(Mitropoulos et al. 2010) and a 71% cure was observed in 79 
patients in Brazil that received 3 injections of 4 mg kg-1day-1 
(Paula et al. 2003). Some authors recommend a single dose 
of 7 mg kg-1 (Oliveira et al. 2011). Formulations in this study 
were prepared with a concentration of 10% commercial PI, 
which represents a dose of 20 mg kg-1day-1.  The hamsters 
each weighed approximately 200g. However, it was possible 
to observe the effects in the period after treatment, and long-
term effects were demonstrated in treatment groups with 
creams containing PI, as the control of the lesions developed. 
Biochemical studies with PI  in promastigote of L. 
amazonensis and L. donovani reported  that this drug gets 
accumulated  inside  the mitochondria and enhances efficacy 
of mitochondrial respiratory chain complex II inhibitors 
suggesting the leishmanicidal activities due to decreased 
mitochondrial membrane potential (Singh et al. 2012). 
However, there were other effects such as the inhibition of 
the use of S-adenosyl-L methionine and prevention of the 
synthesis of important molecules for maintaining the life of 
the parasite (Basselin et al. 1997; Silva-Lopez 2010) which 
may explain cell changes observed by TEM in the treatment 
with topical formulation containing pentamidine, as in ACP 
group.  After analyzing the results of the parasite morphology 
post the treatment, there was the possibility that there was 
penetration of the drug across the epithelial tissues, and 
thus there was the possible preventing of the inflammatory 
response and parasite multiplication that occurs in the benign 
forms of CL in the animals submitted to anhydrous creams, 
particularly containing PI. 
Results of the topical treatment with the diamidine based 
drug Trypan® in BALB/c mice infected with L. donovani  or 
L. major  demonstrated that no effects were observed after 
21 weeks of treatment when applications initiated after the 
lesions were established (Macharia et al. 2004). In this study, 
positive effects were observed in the topical treatment with 
PI, even when the application started after the appearance of 
lesions.  Topical treatment of CL was associated with other 
drugs, such as the formulations containing 15% Paromomycin 
Figure 3. Evaluation of cutaneous leishmaniasis development in hamster 
treated with topical treatment. Clinical aspect of macroscopic lesions in 
Golden Hamster (Mesocricetus auratus) infected by Leishmania (Leishmania) 
amazonensis. A – Control Group:  animals inoculated but without topical 
treatment, image of 3rd day of treatment. B – ACE5AU Group: animals received 
50 mg day-1 of formula with 10% pentamidine isethionate and 10% of usnic 
acid, image of third day of treatment. C - Control Group:  animals inoculated but 
without topical treatment, image of 35th day of treatment. D - ACE5AU Group: 
animals received 50 mg day-1of formula with 10% PI and 10% of usnic acid, 
image of 35rd day of treatment. This figure is in color in the electronic version.
Figure 4. Photomicrography (TEM) of cutaneous lesion of snout tissue from 
hamster (Mesocricetus auratus) infected with Leishmania (Leishmania) 
amazonensis A – amastigote form (am) in host tissue of untreated hamster. 
B – Tissue of a hamster treated with topical formulations containing Pentamidine 
(ACP), presence of (am) amastigotes forms in vacuoles and cellular vesicles (V).
qualitative as no measurement or quantification was observed, 
and to verify the ultrastructure of intracellular amastigotes in all 
treatments that the TEM was used. However, the cell morphology 
of parasites present in the lesions treated with ACP showed 
a suggestive alteration in the tissue visualized by microscopy. 
The results of the TEM demonstrated that the formation of 
parasitophorous vacuoles were containing amastigotes in all 
groups (Figure 4). However, there were morphological changes 
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(El-On et al. 1993), Miltex® (Schmidt-Ott et al. 1999), 
25% podophyllin solution used topically (Sharquie et al. 
2015) and tamoxifen (Eissa et al. 2011), that also used the 
size measurement methodology, clinical, and printing blade 
to monitor the effect of treatment. Also discussed was the 
possibility of using known drugs to develop new treatments 
that are also showing promising results. 
The study showed positive results with 15% Paromomycin 
causing parasite inhibition after 20 days of the application of 
the topical treatment, as do other studies in infection with 
other species of Leishmania (El-On et al. 1993). Our results 
are promising using topical treatments with formulations 
containing PI in lesions caused by L. amazonensis. This can 
be explained by the difference of conventional treatment 
and pharmacological kinetics of paromomycin and PI, when 
time of applications is short with PI.  Larbi et al. (1995) 
found that the topical treatment was effective against CL in 
Saudi Arabia using creams containing 1% clotrimazole and 
miconazole 2% in a randomized, double-blind clinical study. 
In this study, they observed that clotrimazole was the most 
efficient in reducing injuries, but it was still very limited for 
use in the treatment of leishmaniasis, with parasites still at the 
end of treatment. Similar results were observed when active 
promastigotes were found in all treatments after incubation 
of fragments of tissues in NNN. 
Another study using the TT was with imidazoquinoline, a 
drug approved for the treatment of genital warts that showed 
activity against Leishmania by stimulating Nitrous Oxide 
production of infected macrophages and reducing the number 
of parasites. In the study of Miranda-Verastegui et al. (2005), 
which was conducted in the endemic regions of the Peruvian 
Andes and tropical forest, they included 40 patients which 
were infected by L. peruviana and L. braziliensis. However, 
the side effects that were reported in the group treated with 
imiquimod, were erythema, edema, itching, burning and pain 
(Almeida and Santos 2011). The parenteral administration of 
PI caused side effects such as musculoskeletal pains, anorexia, 
abdominal pains, nausea, headaches, asthenia and fatigues 
(Oliveira et al. 2011) could be reduced with a topical treatment 
application. Different creams were compared (anhydrous 
and hydrating) for their effectiveness on lesions with L. 
amazonensis. The ACE5AU treatments showed greater efficacy 
in the control of the developed lesion, but still was not able 
to inhibit parasites after treatment. 
In the composition of the creams, Copaiba oil was 
incorporated, which has demonstrated activity against L. 
amazonensis by oral treatment (Santos et al. 2008), but the 
mechanism of topical application shows less efficacy. The 
leishmanicidal properties of usnic acid has also demonstrated 
some success by in vitro and in vivo experiments (Fournet et 
al. 1997), with a reduction in the weight of lesions and in 
parasite loads. However, Copaiba oil and usnic acid seem to 
have no effect in formulations without pentamidine in lesions 
caused by L. amazonensis, whereas group ACU (Andiroba, 
Copaiba and usnic acid) did not show a reduction in the size 
of lesions or parasite loads. Thus, multi-disciplinary efforts 
continue to be important in developing an effective topical 
treatment for treating CL.   This could be done using new 
active compounds that can work concurrently with known 
drugs that have anti-leishmania action. In fact, the PI  is 
completely absorbed after parenteral administration (Berman 
2005), but the mechanism of action is by inhibiting different 
cellular processes, not yet fully elucidated. 
Topical formulations containing PI have the potential to 
be a promising area of further studies for the treatment of CL. 
In treatment with PI there was observed in the animals treated, 
the presence of edema in the hydrating creams, but in treatment 
without PI,  this effect may be attributed  to formulation.  
CONCLUSIONS
The treatment that demonstrated greater potential in the 
clinical aspects of the disease and efficiency with reduction 
of the total average size of the lesions was the group that 
received the ACE5AU cream. However, in all groups there 
was observed amastigotes without complete reduction of the 
parasites, although the morphological changes in the cells 
reduced the number of parasites when compared with the 
control groups of infected hamsters with L. amazonensis. This 
preliminary study demonstrated the potential of using topical 
treatments to reduce the number of parasites, and also could, 
with the association of others drugs, lead to a faster and more 
effective treatment of cutaneous leishmaniasis.
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